Albiglutide

Peptide

Albiglutide is retained as a catalog identity with independently verified primary-literature context. No qualified exposure model, dose recommendation, efficacy claim, or safety claim is provided.

Pharmacokinetic model

A route-level PK model for albiglutide is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Peptide
Suggested cadence: once daily

Research behind this entry

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators · Lancet (London, England), 2018 DOI
This citation reports a human clinical study involving Albiglutide. It does not establish a qualified human dose, safety profile, efficacy claim, or pharmacokinetic route for this catalog record.

1 published study referenced in the app, each with a plain-language summary.